Upadacitinib safety similar to other JAK inhibitors for rheumatoid arthritis

Reuters Health - 12/11/2020 - A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase (JAK) inhibitors, results from phase 3 clinical trials suggest. Researchers examined data on treatment-emergent adverse events among patients taking upadacitinib in five randomized phase 3 clinical trials with either placebo or active controls. Across all the trials, a total of 3,834 patients took one or more doses of upadacitinib 15 mg (n=2,630) or 30 mg (n=1,204) for a total of 4,020.1 person-years of exposure to the drug. The 15 mg dose of upadacitinib had higher risk of herpes zoster than methotrexate (hazard ratio 2.997) and adalimumab (HR 3.211); this dose also had a higher risk of creatine phosphokinase elevations than placebo (HR 2.314), methotrexate (HR 2.701), and adalimumab (HR 2.588). The 30 mg dose of upadaci...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 12 November, 202020 November, 2020